NCT04433156 2026-04-09
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Phase 2 Completed
Clinical Trials
6 trialsNCT04877821 2026-04-02
NeoSACT
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT06797635 2026-03-13
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT06291064 2026-02-17
TARMAC
University of Chicago
Phase 2 Recruiting
NCT07320508 2026-01-21
EIC-SNACC
Eye & ENT Hospital of Fudan University
Phase 2 Recruiting